REVIEW PAPER
Prolonged activated partial thromboplastin time in pediatric patients – an important diagnostic challenge
More details
Hide details
1
Clinical Department of Pediatrics and Neurology, St. Louis Regional Specialized Children’s Hospital, Kraków, Poland
2
Collegium Medicum, Andrzej Frycz Modrzewski University, Kraków, Poland
3
Department of Hematology and Internal Medicine, Jagiellonian University Medical College, Kraków, Poland
Submission date: 2025-07-28
Final revision date: 2025-08-20
Acceptance date: 2025-09-01
Publication date: 2025-11-24
Corresponding author
Aleksandra Zima
Dr. Aleksandra Zima, Clinical Department of Pediatrics and Neurology, St. Louis Regional Specialized Children’s Hospital, Kraków, Poland
Pediatr Pol 2025;61(4):353-358
KEYWORDS
TOPICS
ABSTRACT
Basic hemostasis tests are among the most frequently performed laboratory investigations in pediatric practice. Therapeutic decisions regarding a child are often based on the results of screening hemostatic tests, such as the activated partial thromboplastin time (aPTT) or prothrombin time. Therefore, careful and accurate interpretation of these tests in the context of the specific patient, their clinical condition, and medical history is crucial for making the correct diagnosis. Although in most pediatric cases, aPTT prolongation is caused by pre-analytical errors, one must not overlook the possibility of underlying plasma coagulation disorders. In this article, we also highlight the relationship between the presence of mild plasma coagulation disorders and prolonged aPTT values.
REFERENCES (17)
1.
Santoro RC, Molinari AC, Leotta M, Martini T. Isolated prolongation of activated partial thromboplastin time: not just bleeding risk! Medicina 2023; 59: 1169.
2.
Sierra C, Moreno M, García-Ruiz JC. The physiology of hemostasis. Blood Coagul Fibrinolysis 2022; 33: S1-S2.
3.
Loizou E, Mayhew D, Martlew V, Murthy BVS. Implications of deranged activated partial thromboplastin time for anaesthesia and surgery. Anaesthesia 2018; 73: 1557-1563.
4.
Chojnowski K, Podolak-Dawidziak M, Windyga J. Diagnosis of the prolonged activated partial thromboplastin time (aPTT). Hematologia 2010; 1: 81-86.
5.
Zdziarska J, Chojnowski K, Klukowska A, Łaguna P, Łętowska M, Mital A, et al. Postępowanie w chorobie von Willebranda. Zalecenia Grupy ds. Hemostazy Polskiego Towarzystwa Hematologów i Transfuzjologów 2022. J Transfus Med 2022; 15: 100-126.
6.
Blanchette VS, Kahr WHA. Work-up of a bleeding child. In: Lee CA, Berntorp EE, Hoots KW (eds.). Textbook of hemophilia. Blackwell Publishing, Oxford 2005, 112-119.
7.
Toulon P, Berruyer M, Brionne-François M, Grand F, Lasne D, Telion C, et al. Age dependency for coagulation parameters in paediatric populations. Results of a multicentre study aimed at defining the age-specific reference ranges. Thromb Haemost 2016; 116: 9-16.
8.
Rasmussen KL, Philips M, Tripodi A, Goetze JP. Unexpected, isolated activated partial thromboplastin time prolongation: a practical mini-review. Eur J Haematol 2020; 104: 519-525.
9.
Liu J, Li F, Shu K, Chen T, Wang X, Xie Y, et al. The analysis of false prolongation of the activated partial thromboplastin time (activator: Silica): interference of C-reactive protein. J Clin Lab Anal 2018; 32: e22571.
10.
Erdem-Eraslan L, Hens JJH, van Rossum AP, Frasa MAM, Keuren JFW. Inter-individual variability in phospholipid-dependent interference of C-reactive protein on activated partial thromboplastin time. Br J Haematol 2018; 183: 681-683.
11.
Tripodi A. Laboratory testing for lupus anticoagulants: a review of issues affecting results. Clin Chem 2007; 53: 1629-1635.
12.
Betensky M, Mosha M, Tarango C, Verma A, Bhat R, Kucine NE, Nakano T, et al. Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial. Blood Adv 2024; 8: 5790-5795. .
13.
Halbmayer WM, Haushofer A, Schon R, Mannhalter C, Strohmer E, Baumgarten K, et al. The prevalence of moderate and severe FXII (Hageman factor) deficiency among the normal population: evaluation of the incidence of FXII deficiency among 300 healthy blood donors. Thromb Haemost 1994; 71: 68-72.
14.
Schmaier AH. The elusive physiologic role of Factor XII. J Clin Invest 2008; 118: 3006-3009.
15.
Mouthon P, Guy A, d’Oiron R, Harroche A, Lebreton A, Gourguechon C, et al. Acquired haemophilia A in paediatric patients: a retrospective French cohort of eight cases. Br J Haematol 2024; 204: 606-611.
16.
Windyga J, Chojnowski K, Klukowska A, Łaguna P, Łętowska M, Mital A, et al. Emicizumab (Hemlibra®) u chorych na hemofilię A powikłaną inhibitorem czynnika VIII – wytyczne Grupy ds. Hemostazy Polskiego Towarzystwa Hematologów i Transfuzjologów. J Transf Med Hemost 2020; 13: 153-164.
17.
Feriel J, Goujon MA, Desez M, Depasse F. Impact of drugs used in intensive care on routine coagulation testing. Diagnostics (Basel) 2025; 15: 941.